CURRICULUM VITAE

Holbrook E.K. Kohrt, M.D. Ph.D.

Personal Data

Business Address Division of Oncology, CCSR 1110

269 Campus Drive

Stanford University Medical Center

Stanford, California 94305

Academic History

2000 Muhlenberg College, B.S.

Molecular Biology, Summa cum laude, valedictorian

2005 Stanford University, M.D.2011 Stanford University, Ph.D.

Clinical Trial Design and Tumor Immunology

Professional Experience

1/01/2012 – 4/26/2012 Instructor of Medicine, Division of Oncology

Stanford University School of Medicine

4/27/2012 – present Assistant Professor of Medicine, Division of Oncology

Josephine Berry Scholar

Stanford University School of Medicine

Pre/Post-Doctoral and Residency Training

2004-2005 Howard Hughes Medical Institute Research Training

Fellowship, Stanford, California

2005-2007 Internship and Residency in Internal Medicine, Stanford

University Medical Center, Stanford, California

Clinical Investigator Pathway

2007-2011 Fellow, Department of Medicine, Divisions of Hematology

and Oncology, Stanford University Medical Center,

Stanford, California

Advanced Research Training Pathway (Ph.D.)

2008 Stanford Center for Clinical and Translational Education

and Research Training Program

2009 American Society of Bone Marrow Transplantation Clinical

Research Training Program

2009 American Society of Hematology Clinical Research

Training Institute Training Program

Certification and Licenses

2006 Board Certification, Internal Medicine

State of California Medical License #A96219

Research Experience

1997 **Nonrandom Mating of** *Marabilis jalapa* Muhlenberg College,

Richard Niesenbaum, Ph.D. Designed pollen competition mating pairs

to support theory of a 'super-pollen'.

1999 Cross-cultural Stress Syndromes. Mongolia, Co-director of

research team sponsored by the National Medical University of Mongolia. Examined the epidemiology and pathogenesis of *yadargaa*, a culture-bound syndrome in Mongolia by conducting patient, physician and community assessment. Organized production of an

amateur documentary, The Wrestler's Second.

1998-2000 Cloning and Characterization of *unc-20*. Muhlenberg College,

Bruce Wightman, Ph.D. Characterized the phenotypic and molecular role of *Unc-20* expression in *C. elegans* with gene cloning analysis by candidate clone recovery, strain mating, and dsRNA interference.

2002 Child Maltreatment, Mental Illness, and HPA Reactivity. Mongolia,

Directed a research team sponsored by Mongolia-based Agency for the Prevention and Protection of Children from Abuse and Neglect. Evaluated cortisol response, psychiatric epidemiology, and

ethnography to model the developmental effects of child abuse on

young boys in Mongolia.

2003-2004 Heterogeneity in T Cell Response following Cancer Vaccination.

Stanford University, Peter Lee, M.D. Elucidated novel heterogeneity in CD8 T cell response to tumor among patient samples inoculated with melanoma vaccine. Developed a unique method of modeling

differential dynamics of T cell receptor downregulation.

2004-2008 Bay Area Sentinel Lymph Node Study. Stanford University,

Stefanie Jeffrey, M.D. Facilitated organization and analysis of a patient database of over one thousand breast cancer patients in Northern California incorporating seventeen hospitals and fifty-one physicians. Database analysis performed includes investigating clinicopathologic predictors of false-negative sentinel lymph nodes, sentinel lymph node micrometastasis, and non-sentinel lymph node

metastasis.

2003-2008 **Tumor-draining Lymph Node Analysis**. Stanford University, Peter

Lee, M.D. Investigated tumor-immune interactions within primary and secondary echelon lymph nodes of patients with breast cancer and melanoma by immunohistochemistry, flow cytometry, computer

modeling and microarray analysis.

2009-present

Therapeutic Strategies to Enhance Anti-tumor Immunity.
Stanford University, Sam Strober, M.D.; Ron Levy, M.D.; Robert
Lowsky, M.D. Investigation of preclinical models of bone marrow
transplantation and immunomodulatory antibody therapy provides the
platform for translation to early phase clinical trials. Specific areas
include:

- 1. Immune Cell Allotransplantation for Curing Cancer: To develop novel vaccine strategies which induce tumor antigen specific immunity prior to infusing the donor inoculum and improve graft-versus-tumor reactions without exacerbation of graft-versus-host disease.
- 2. Augmenting Antibody Therapy for Curing Cancer: To identify and develop immunomodulatory antibodies targeting immune effector cells subsets, such as natural killer cells, which enhance the anti-tumor activity of tumor-targeting antibodies. Investigating capacity of active immunotherapy in solid tumors to produce anti-tumor immune response following stem cell transplantation and in the setting of transferred allogeneic combined immunotherapy and stem cell transplantation. Research incorporates mouse modeling and two clinical trials.

Teaching Activities

2007 Cancer Education Seminar Series, "Dendritic and Histiocytic

Neoplasms", Stanford University Division of Oncology, March 24,

2007

2009-present Didactic talks on Med X Inpatient Service, "Diagnosis and

Management of Non-Hodgkin Lymphoma"

2010-present Stanford Internal Medicine Residency Education Series,

"Thrombocytopenia"

2012 Cancer Education Seminar Series, "Modulating the Immune

Response, The Future of Cancer Therapy", Stanford University

Division of Oncology, January 24, 2012

Positions and Employment

2009-present Stanford Clinical Trials Monitoring Board, *volunteer*

member

2009-present Research Match Clinical Trial Foundation, CTSA-

sponsored, Stanford liaison

2009-present Stanford Institute of Medicine Research Program,

volunteer mentor

Honors, Scholarships and Awards

1996 Bausch & Lomb Honorary Science Award

1996 Pennsylvania Governor's Award for Exceptional

Community Service

1996 Rotary Service Above Self Award

1996	American Red Cross Board of Supervisors District Service Award
1996	Eagle Scout Honorary Award
1996	Pennsylvania Department of Health (\$140k)
1996	Big 33 State Scholarship
1996-1997	National Hemophilia Foundation Scholarship
1996-2000	Coca-Cola Scholarship
1996-2000	Presidential Scholarship
1997	Alpha Phi Omega Service Award
1999	Alpha Epsilon Delta Alumni Scholarship
2000-2005	Delia and Ronald Baxter Scholarship (merit-based full tuition/stipend scholarship)
2000	Lichtenwalner Memorial Science Award
2000	Phi Beta Kappa
2000	President's Award for Academic Excellence
2004	Stanford School of Medicine Alumni Award for Presentation of Research
2005 & 2006	American College of Physicians Regional Research Scholar Award
2006 & 2007	Franklin G. Ebaugh, Jr. Award for Research
2007	Stanford Annual Award for Outstanding Clinical Teaching by Housestaff
2008	New England Journal of Medicine Editorial Contest, 1 st prize
2008-2011	Advanced Research Training Scholarship
2008	Stanford Center for Clinical and Translational Education and Research Scholar
2009	American Society of Bone Marrow Transplantation Clinical Research Course Scholar
2009	American Society of Hematology Clinical Research Training Institute Scholar
2009	Stanford Center for Clinical and Translational Education and Research Mentor
2009	XXIV Symposium of the International Association for Comparative Research of Leukemia and Related Diseases Travel Award
2010	Deborah L. Faiman Young Investigator's Award
2010	American Society of Hematology Travel Award
2010	Stanford Center for Clinical and Translational Education and Research Mentor
2010	Current Methods for Translational Research in Human Immunology (METiS) Scholar
2011	Burroughs Wellcome Fund CAMS Finalist

Josephine Berry Scholar 2012 Damon Runyon Clinical Investigator Award France-Stanford Center for Interdisciplinary Studies Grant 2012 Grants Past: 1999 Muhlenberg College Research Grant 2001 Stanford University School of Medicine International Research Grant 2003-2004 American Society of Hematology Research Fellowship 2004-2005 Howard Hughes Medical Institute Research Training Fellowship (PI: Peter Lee) T32 Training Grant "Hematopoietic Cell Transplantation" – Ruth L. 2009-2010 Kirschstein National Research Service Award (Ronald Levy and Sam Strober, PI and mentors) Funder: Stanford University School of Medicine, Dean's 2010-2011 Postdoctoral Fellowship Leukemia-peptide vaccination of allogeneic transplant donors & recipients with hematologic malignancies Role: PI 2010-2011 Funder: American Society of Clinical Oncology, Young Investigator's Award (ASCO YIA) Title: A Phase I trial of PR1 peptide immunization of matched related donors and recipients with Acute Myeloid Leukemia and Myelodysplastic Syndrome receiving reduced intensity conditioning for allogeneic hematopoietic cell transplantation Role: PI 2010-2011 Funder: American Society of Hematology, Research Training Award for Fellows (ASH RTAF) A Phase I trial of PR1 peptide immunization of matched related donors and recipients with Acute Myeloid Leukemia and Myelodysplastic Syndrome receiving reduced intensity conditioning for allogeneic hematopoietic cell transplantation Role: PI 2010-2011 Funder: California Breast Cancer Research Program Title: Enhancing trastuzumab therapy with an NK activating antibody Role: Co-Investigator (PI: R. Levy) 2010-2011 Funder: Nadia's Gift Foundation Investigation of putative biomarkers of CD137 therapy Role: Co-PI (PI: R. Levy) Present/Pending: Funder: Reliable Cancer Research Fund 2010-2015 Title: Enhancing NK cell function with anti-CD137 monoclonal antibody Role: Co-PI (PI: R. Levy) 2010-2014 Funder: EUREKA, NIH & NCI (R01) Enhancing tumor-targeted antibody therapy with a second NK activating antibody Role: Co-Investigator (PI: R. Levv) 2011-2014 Funder: American Society of Hematology, Scholar Award

2012

Title: A Phase I trial of PR1 peptide immunization of matched related donors and recipients with Acute Myeloid Leukemia and

Myelodysplastic Syndrome receiving reduced intensity conditioning for allogeneic hematopoietic cell transplantation

Role: PI

2011-2014 Funder: Leukemia and Lymphoma Society Special Fellow in

Clinical Research Award

Title: Leukemia-peptide vaccination of allogeneic transplant

donors & recipients

Role: PI

2011-2014 Funder: Department of Defense Breast Cancer Research Program

of the Office of the Congressionally Directed Medical Research

Programs, Postdoctoral Fellowship Award

Title: Augmenting trastuzumab therapy against breast cancer

through selective activation of NK cells

Role: PI

2012-2015 Funder: Damon Runyon Clinical Investigator Award

Title: Augmenting anticancer antibody therapies through

selective activation of NK cells

Role: PI

2012-2015 Funder: France-Stanford Center for Interdisciplinary Studies Grant

Title: Synergy of Targeted and Immune Therapies Combination:

Proof of Concept

Role: Co-PI (Co-PI: Aurelien Marabelle)

Clinical Trials

4/23/2010 – present STUDY: FNA Tumor Sampling for CD137 Modulation: A Pilot Study.

ROLE: Co-principal investigator PI: Dimitrios Colevas, MD

STUDY TYPE: Investigator-initiated single institution trial

SPONSOR: NIH (EUREKA)
SUBJECTS: # at Stanford: 75
NCT ID: NCT01114256

2/28/2011 – present STUDY: A Phase 1 Study Of PF-05082566 As A Single Agent And

In Combination With Rituximab.

ROLE: Stanford Site PI (multi-site trial at Stanford)

STUDY TYPE: Industry-initiated multi-institutional trial based on

Stanford pre-clinical research

SPONSOR: Pfizer

SUBJECTS: # at Stanford: 18 overall: 78

NCT ID: NCT01307267

6/20/2007 – present STUDY: Phase I/II of a CpG-Activated Whole Cell Vaccine

Followed by Autologous Immunotransplant for MCL ROLE: Co-investigator PI: Ron Levy, MD STUDY TYPE: Investigator-initiated single institution trial

SPONSOR: Leukemia and Lymphoma Society

SUBJECTS: # at Stanford: 30 NCT ID: NCT00490529

4/10/2009 – present STUDY: A Phase II Intratumoral Injection PF-3512676 Plus Local

Radiation in Low-Grade B-Cell Lymphomas

ROLE: Co-investigator PI: Ron Levy, MD

STUDY TYPE: Investigator-initiated single institution trial

SPONSOR: Pfizer

SUBJECTS: # at Stanford: 30 NCT ID: NCT00880581

7/12/2010 – present STUDY: Phase II Study of Velcade for Relapsed or Refractory T-

cell Prolymphocytic Leukemia

ROLE: Co-investigator PI: Bruno Medeiros, MD STUDY TYPE: Investigator-initiated single institution trial

SPONSOR: Millennium
SUBJECTS: # at Stanford: 17
NCT ID: NCT01162031

9/12/2005–7/13/2010 STUDY: Phase I/II CPG 7909 + Local XRT in Recurrent Low-

Grade Lymphomas

ROLE: Co-investigator PI: Ron Levy, MD STUDY TYPE: Investigator-initiated single institution trial

SPONSOR: Lymphoma Research Foundation

SUBJECTS: # at Stanford: 30 NCT ID: NCT00185965

Clinical Trials - Pending

awaiting regulatory approval Phase I study of two dosing schedules of subcutaneous

rhIL-15 for advanced malignancies. Co-principal

investigator

awaiting IND Phase I Study of PR-1 Vaccination of Allogeneic Donor in

Combination with Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. *Co-principal investigator*

Society Memberships

American College of Physicians

American Association for Cancer Research American Society of Clinical Oncology American Society of Hematology

Publications (peer-reviewed) 34 total; 32 published, 2 in press.

- 1. **Kohrt, H**, Kohrt, B, Waldman, D, Saltzman, K, and V Carrion (2004). "An ecological-transactional model of significant risk factors for child psychopathology in Outer Mongolia." <u>Journal of Child Psychiatry and Human Development</u>, **35**(2): 163-181.
- 2. Kohrt, B, Hurschka, D, **Kohrt, H**, Panebianco, N, and G Tsagaankhuu (2004). "Distribution of distress in post-socialist Mongolia: a cultural epidemiology of *yadargaa*." <u>Social Science and Medicine</u>, **58**(3): 471-485.
- 3. **Kohrt, H**, Chen, T, Stuge, T, Webber, J, Holmes, S, and P Lee (2005). "Rapid assessment of recognition efficiency and functional capacity of antigen-specific T cell responses." <u>Journal of Immunotherapy</u>, **28**(4): 297-305.
- 4. **Kohrt, H**, Nowels, K, Johnson, D, and P Lee (2005). "Profile of immune cells in axillary nodes predicts disease-free survival in breast cancer." <u>PLoS Medicine</u>, **2**(9): e284, 904-919.

- 5. **Kohrt, H**, Logan, A, Temmins, C, Witteles, R, Leidtke, M, and B Medeiros (2008). "Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma." <u>Leukemia and Lymphoma</u>, **49**(3), 581-5.
- 6. Kao, D, **Kohrt, H**, and J Kugler (2008). "Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use." <u>Diabetic Medicine</u>, **25**(10), 1229-1230.
 - *Participated extensively in drafting and revision of manuscript.
- 7. **Kohrt, H**, Olshen,RA, Bermas, HR, Goodson, WH, Henry, S, Rouse, RV, Bailey, L, Philben, VJ, Dirbas, FM, Dunn, JJ, Johnson, DL, Wapnir, IL, Carlson, RW, Stockdale, FE, Hansen, NM, and SS Jeffrey (2008). "New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients." <u>BMC Cancer</u>, **8**(66), 1-45.
- 8. **Kohrt, H**, Turnbull, B, Heydari, K, Shizuru, J, Laport, G, Miklos, D, Johnston, L, Arai, S, Weng, WK, Hoppe, R, Lavori, P, Blume, K, Negrin, S, Strober S, and R Lowsky (2009). "TLI and ATG conditioning with low risk of graft-versus-host disease retains anti-tumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors." <u>Blood</u>, **114**(5):1099-109.
- 9. Houot, R, Goldstein, M, **Kohrt, H**, Myklebust, J, Alizadeh, A, Lin, J, Irish, J, Torchia, J, Kolstad, A, Chen, L, and R Levy (2009). "Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion." Blood, **114**(16):3431-8.
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 10. Medeiros, BC, **Kohrt, H**, Arber, D, Bangs, C, Cherry, A, Majeti, R, Kogel, K, Azar, C, Patel, S, and A Alizadeh (2009). "Immunophenotypic features of Acute Myeloid Leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)." Leukemia Research, **34**(5):594-7.
 - *Participated extensively in research concept and design, analysis and interpretation of data, drafting and revision of manuscript.
- 11. **Kohrt, H**, Johannsen, A, Hoppe, R, Horning, S, Rosenberg, S, Advani, R, and P Lee (2009). "Dynamic CD8 T cell responses to tumor-associated Epstein-Barr Virus antigens in patients with Epstein-Barr Virus negative Hodgkin's Disease." Oncology Research, **18**(5-6):287-92.
- 12. Chao, M, Alizadeh, A, Tang, C, Myklebust, J, Varghese, B, Gill, S, Jan, M, Cha, A, Chan, C, Tan, B, Zhao, F, Kohrt, H, Park, C, Malumbres, R, Briones, J, Gascoyne, R, Lossos, I, Levy, R, Weissman, I, and R Majeti (2010). "Anti-CD47 antibody synergizes with rituximab to eradicate non-Hodgkin lymphoma through Fc receptor-independent and dependent mechanisms." <u>Cell</u>, 142(5):699-713.
 - *Participated in performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 13. Setiadi, A, Ray, N, **Kohrt, H,** Kapelner, A, Carcamo-Cavazos, V, Levic, E, Yadegarynia, S, van der Loos, C, Schwartz, E, Holmes, S, and P Lee (2010). "Quantitative, architectural analysis of T and B cells distributions in tumor-draining lymph nodes from breast cancer patients and healthy lymph nodes." PLoS One, **5**(8):e12420.
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 14. **Kohrt, H**, Patel, P, Ho, M, Owen, T, Pollyea, D, Majeti, R, Gotlib, J, Coutre, S, Liedtke, M, Berube, C, Alizadeh, A, and BC Medeiros (2010). "Second line mitoxantrone, etoposide, and

- cytarabine for acute myeloid leukemia: A single-center experience." <u>American Journal of Hematology</u>, **85**(11):877-881.
- 15. Goldstein, M, Varghese, B, Brody, J, Rajapaska, R, **Kohrt, H,** Czerwinski, D, Levy, S, and R Levy (2011). "A CpG loaded tumor cell vaccine induces anti-tumor CD4 T cells that are effective in adoptive immunotherapy for large and established tumors." <u>Blood</u>, **117**(1):118-127.
 - *Participated in performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 16. **Kohrt, H,** Houot, R, Goldstein, M, Weiskopf, K, Alizadeh, A, Mueller, A, Pachynski, R, Czerwinski, D, Coutre, S, Chao, M, Chen, L, Tedder, T, and R Levy (2011). "CD137 stimulation enhances anti-tumor activity of rituximab." <u>Blood</u>, **117**(8):2423-2432.
- 17. Dutt, S, Baker, J, **Kohrt, H**, Kambham, N, Sanyal, M, Negrin, R, and S Strober (2011). "CD8⁺ CD44^{hi} but not CD4⁺ CD44^{hi} memory T cells mediate potent graft anti-lymphoma activity without GVHD." <u>Blood</u>, **117**(11):3230-3239.
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 18. Wei, A, **Kohrt, H,** Timmerman, J, Hsu, F, Taidi, B, Czerwinski, D, and R Levy (2011). "Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma." <u>American Journal of Hematology</u>, **86**(6):515-518.
 - *Participated extensively in research concept and design, analysis and interpretation of data, drafting and revision of manuscript.
- 19. Brody, J, **Kohrt, H,** Marabelle, A, and R Levy (2011). "Active and passive immunotherapy for lymphoma: proving principles and improving results." <u>Journal of Clinical Oncology</u>, **29**(14)1864-1875.
 - *Participated extensively in drafting and revision of manuscript.
- 20. Chang, G, **Kohrt, H**, Stuge, T, Schwartz, E, Weber, J, and P Lee (2011). "Cytotoxic T Lymphocyte Responses Against Melanocytes and Melanoma." <u>Journal of Translational Medicine</u>, **9**(122):1-10.
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 21. Alizadeh, A, Gentles, A, Alencar, A, Liu, C, **Kohrt, H,** Houot, R, Goldstein, M, Zhao, S, Natkunam, Y, Advani, R, Gascoyne, R, Briones, J, Tibshirani, R, Myklebust, J, Plevritis, S, Lossos, I, and R Levy (2011). "Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes reflecting tumor and microenvironment." <u>Blood</u>, **118**(5):1350-1358.
 - *Participated extensively in research concept and design, analysis and interpretation of data, drafting and revision of manuscript.
- 22. **Kohrt, H,** Mueller, A, Baker, J, Goldstein, M, Newell, E, Dutt, S, Czerwinski, D, Lowsky, R, and S Strober (2011). "Donor immunization with WT1 peptide augments anti-leukemic activity after MHC-matched bone marrow transplantation." Blood, **118**(19):5319-5329.
- 23. Yao, Z, Jones, J, **Kohrt, H**, and S Strober (2011). "Selective resistance of CD44hi T Cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation." <u>Journal of Immunology</u>, **187**(8):4100-4108.
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.

- 24. Pollyea, D, **Kohrt, H,** Gallegos, L, Figueroa, M, Abdel-Wahab, O, Zhang, B, Bhattacharya, S, Zehnder, J, Liedtke, M, Gotlib, J, Coutre, S, Berube, C, Melnick, A, Levine, R, Mitchell, B, and B Medeiros (2011). "Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia." <u>Leukemia</u>, epublication Oct 28.
 - *Participated extensively in research concept and design, analysis and interpretation of data, drafting and revision of manuscript.
- 25. Medeiros, B, **Kohrt, H**, Gotlib, J, Coutre, S, Zhang, B, Arber, D, and J Zehnder (2012). "Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia." <u>American Journal of Hematology</u>, **87**: 45-50.
 - *Participated extensively in research concept and design, analysis and interpretation of data, drafting and revision of manuscript.
- 26. McClellan, S, **Kohrt, H,** Coutre, S, Gotlib, J, Majeti, R, Alizadeh, A, and B Medeiros (2012). "Treatment advances have not improved the early death rate in acute promyelocytic leukemia." <u>Haematologica</u>, **97**(1):133-136.
 - *Participated extensively in research concept and design, analysis and interpretation of data, drafting and revision of manuscript.
- 27. Mueller, A, **Kohrt, H**, Cha, S, Laport, G, Klein, J, Guardino, A, Johnston, L, Stockerl-Goldstein, K, Hanania, E, Juttner, C, Blume, K, Negrin, R, Weissman, I, and J Shizuru (2012). "Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells." <u>Biology of Blood and Marrow Transplantation</u>, **118**(1):125-133.
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 28. **Kohrt, H,** Houot, R, Weiskopf, K, Goldstein, M, Scheeren, F, Czerwinski, D, Colevas, AD, Weng, WK, Clarke, M, Carlson, R, Stockdale, F, Mollick, J, Chen, L, and R Levy (2012). "Trastuzumab efficacy in HER2/neu-positive breast cancer is enhanced by stimulation of activated natural killer cells with an antibody to CD137." <u>Journal of Clinical Investigation</u>, **122**(3):1066-1075.
- 29. Mueller, A, Shashidhar, S, Kupper, N, **Kohrt, H,** Florek, M, Negrin, R, Brown, J, and J Shizuru (2012). "Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity." <u>Proceedings of the National Academy of Sciences</u>, **109**(15):5820-5825.
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 30. Goldstein, M, **Kohrt**, **H**, Houot, R, Varghese, B, Lin, JT, Swanson, E, and R Levy (2012). "Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137 expressing regulatory T cells. <u>Cancer Research</u>, **72**(5):1239-46.
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 31. Warlick, E, Ahn, K, Pederson, T, Artz, A, deLima, M, Pulsipher, M, Akpek, G, Aljurf, M, Cahn, J, Cairo, M, Chen, Y, Cooper, B, Deol, A, Giralt, S, Gupta, V, Khoury, H, **Kohrt, H**, Lazarus, H, Lewis, I, Olsson, R, Pidala, J, Savani, B, Seftel, M, Socie, G, Tallman, M, Ustun, C, Vij, R, Vindelov, L, and D, Weisdorf (2012). "RIC is superior to NMA conditioning for older Chronic

- Myelogenous Leukemia patients undergoing Hematopoietic Cell Transplant during the TKI era." <u>Blood</u>, March 9, e-pubication date.
- *Participated in research concept and design, analysis and interpretation of data, drafting and revision of manuscript.
- 32. Gill, S, Vasey, A, DeSouza, A, Baker, J, Smith, A, **Kohrt, H,** Florek, M, Gibbs, K, Tate, K, Ritchie, D, and R Negrin (2012). "Rapid development of exhaustion and downregulation of eomesodermin limits the anti-tumor activity of adoptively transferred murine natural killer cells." Blood, April 27, e-publication date.
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 33. Anderson, M, Zhao, S, Freud, A, Czerwinski, D, **Kohrt, H**, Alizadeh, A, Houot, R, Azambuja, D, Morais, J, Spector, N, Molina-Kirsch, H, Warnke, R, Levy, R, and Y Natkunam (2012). "CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T cell lymphomas: Diagnostic and Therapeutic Implications." "American Journal of Pathology", (in press).
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.
- 34. Pachynski, R, Zabel, B, Tejeda, N, Alizadeh, A, Monnier, J, Swanson, C, Holzer, A, Sperinde, G, **Kohrt, H,** Hadeiba, H, and E Butcher (2012). "The chemoattractant chemerin suppresses melanoma by recruiting innate anti-tumor defenses." <u>Journal of Experimental Medicine</u>, (in press).
 - *Participated extensively in research concept and design, performance of experiments, analysis and interpretation of data, drafting and revision of manuscript.

Publications (review articles) 15 total; 14 published, 1 in press

- 1. **Kohrt, H**, Ouyang, D, and Keeffe (2006). "Systematic review: Lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection." <u>Alimentary</u> Pharmacology and Therapeutics, **24**, 1003-1016.
- 2. **Kohrt, H,** Ouyang, D, and Keeffe (2007). "Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection." Clinics in Liver Disease, **11**(4), 965-991.
- 3. **Kohrt, H,** and E Keeffe (2007). "Antiviral prophylaxis for patients with chronic hepatitis B who require chemotherapy." <u>Current Hepatitis B Reports</u>, **1**, 42-48.
- 4. **Kohrt, H,** and E Keeffe (2007). "Antiviral prophylaxis for patients with chronic hepatitis B who require chemotherapy." <u>Current Hepatitis Reports</u>, **6**, 166-172 (select manuscripts from Current Hepatitis B Reports).
- 5. **Kohrt**, **H**, and S Coutre (2008). "Optimizing therapy for acute myeloid leukemia." <u>Journal of the National Comprehensive Cancer Network</u>, **6**(10): 1003-1016.
- 6. **Kohrt, H**, and R Lowsky (2009). "Total lymphoid irradiation for graft-versus-host disease protection." <u>Current Opinion in Oncology</u>, **21**(1):S23-6.
- 7. **Kohrt, H**, and R Lowsky (2009). "Non-myeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update." <u>Current Opinion in Hematology</u>, **16**(6):460-5.
- 8. **Kohrt**, **H**, and T George (2009). "Assessment of neutrophilia." <u>British Medical Journal Best Practice</u>, 29321023:1-18.

- 9. **Kohrt**, **H**, and R Advani (2009). "Extranodal natural killer / T-cell lymphoma: current concepts in biology and treatment." <u>Leukemia and Lymphoma</u>, **50**(11):1773-84.
- 10. **Kohrt, H,** Pillai, A, Lowsky, R, and S Strober (2010). "Natural killer T cells, T regs, and their interactions in bone marrow transplantation." <u>European Journal of Immunology</u>, **40**(7):1862-9.
- 11. **Kohrt, H,** Lee, M, and R Advani (2010). "Risk stratification in NK/T cell lymphoma." <u>Expert Review of Anticancer Therapy</u>, **10**(9):1395-1405.
- 12. Pollyea, D, **Kohrt, H,** and B Medeiros (2011). "Acute myeloid leukemia in elderly patients." <u>British Journal of Hematology</u>, **152**(5):524-542.
- 13. Houot, R, **Kohrt, H,** Goldstein, M, and R Levy (2011). "Immunomodulating antibodies for the treatment of hematological malignancies." <u>Cancer Metastasis Reviews</u>, **30**(1):97-109.
- 14. **Kohrt, H,** Houot, R, Marabelle, A, and R, Levy (2011). "Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy." <u>Trends in Immunology</u>, **32**(11):510-516.
- 15. **Kohrt, H,** Houot, R, Marabelle, A, Brody, J, and R Levy (2012). "Combination therapy to enhance ADCC activity." <u>Immunotherapy</u>, (in press).

Editorials and Letters 3 total

- 1. **Kohrt, H**, Patel, P, Ho, M, Owen, T, Pollyea, D, Majeti, R, Gotlib, J, Coutre, S, Liedtke, M, Berube, C, Medeiros, BC, and A Alizadeh (2010). "*Is time of the essence in adult Acute Myeloid Leukemia?* Time to induction therapy and peripheral blood blast clearance as outcome predictors." <u>Blood</u>, (e-letter, April 1, 2010).
- 2. **Kohrt, H**, Ohgami, R, Arber, D, Alizadeh, A, and S. Coutre (2011). "Diagnosing PNH in the era of FLAER." <u>Blood</u>, (e-letter, November 9, 2011).
- 3. Goldstein, M, and **H Kohrt** (2012). "What happened to the Physician-Scientist?" <u>Academic Medicine</u>, **87**(2):132-3.

Published Abstracts 36 total

- 1. **Kohrt, H**, and B Wightman (1999). "Molecular cloning strategies of *unc-20*." <u>Proceedings of Society of Developmental Biology</u>, **2**: 12-13.
- 2. **Kohrt, H**, Nowels, Johnson, and P Lee (2004). "Non-sentinel lymph node status among breast cancer patients: predictors and false-negative findings." <u>American Journal of Clinical Pathology</u>, **122**: 644.
- 3. **Kohrt, H,** Nowels, K, Johnson, D, and P Lee (2004). "Immune profile of sentinel and non-sentinel lymph nodes among breast cancer patients: evidence of immune dysregulation." <u>Breast Cancer Research and Treatment</u>, **91**(88): S244.
- 4. **Kohrt, H**, Chen, Stuge, and P Lee (2004). "Heterogeneity within antigen-specific T cell responses revealed by differential dynamics of TCR downregulation." <u>Blood</u>, **104**(11): 3851.
- 5. **Kohrt, H**, Olshen, Goodson, Rouse, Bailey, Philben, Dirbas, Stockdale, Carlson, and S Jeffrey for the Bay Area SLN Study Group (2006). "Predicting non-sentinel lymph node involvement in breast cancer." <u>Journal of Clinical Oncology</u>, **24**(18S): 10s.
- 6. **Kohrt, H**, Turnbull, B, LaPort, G, Miklos, D, Shizuru, J, Johnston, L, Arai, S, Weng, WK, Benjamin, J, Blume, K, Negrin, R, Lavori, P, Strober, S, and R Lowsky (2008). "Outcomes

- following allogeneic HCT using NMA conditioning with TLI and ATG confirm a low incidence of graft versus host disease with retained anti-tumor activity." Blood, **112**: 3310.
- 7. **Kohrt**, **H**, and S Schrier (2008). "Fish mouth vertebrae and sickle cell spine." <u>Blood</u>, <u>ASH Image Bank</u>, d-08-0056.
- 8. **Kohrt, H,** Kapelner, A, Holmes, S, and P Lee (2008). "An interactive statistical imaging system and pilot application to characterize axillary lymph nodes in breast cancer." <u>Journal of Clinical Oncology</u>, **26**: 11059.
- 9. **Kohrt, H**, Advani, R, Hoppe, R, Rosenberg, S, Horning, S, and P Lee (2009). "Dynamic CD8 T-cell responses to tumor-associated EBV antigens in patients with EBV-negative Hodgkin Disease." <u>Journal of Clinical Oncology</u>, **27**: 8573.
- 10. Alizadeh, A, McClellan, J, Gotlib, J, Coutre, S, Majeti, R, **Kohrt, H**, and BC Medeiros (2009). "Early mortality in acute promyelocytic leukemia may be higher than previously reported." <u>Blood</u>, **114**: 1015.
- 11. Dutt, S, Baker, J, Kambham, N, **Kohrt, H**, Negrin, R, and S Strober (2009). "Memory phenotype CD8+T cells are superior to naive CD8+T cells in separating graft anti-tumor activity from GvHD after bone marrow transplantation; application to DLI." ." Blood, **114**: 2452.
- 12. Logan, A, Su, R, George, T, **Kohrt, H**, Medeiros, B, and A Alizadeh (2009). "High risk of early mortality in adult patients with acquired hemophagocytic lymphohistiocytosis." <u>Blood</u>, **114**: 1359.
- 13. Goldstein, M, Houot, R, **Kohrt, H,** Brody, J, and R Levy (2009). "Adoptive therapy for lymphoma with CD4 memory T cells depleted of CD137-expressing Tregs." <u>Blood</u>, **114**: 1693.
- 14. Alizadeh, A, Gentles, A, Alencar, A, **Kohrt, H,** Houot, R, Talreja, N, Shyam, R, Natkunam, Y, Gascoyne, R, Briones, J, Advani, R, Lossos, I, and R Levy (2009). "Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes: Integration of tumor and microenvironment contributions." <u>Blood</u>, **114**: 622.
- 15. Houot, R, Goldstein, M, **Kohrt, H,** Myklebust, J, Alizadeh, A, Lin, J, Irish, J, Torchia, J, Kolstad, A, Chen, L, and R Levy (2009). "Therapeutic potential of anti-CD137 antibody in lymphoma." Blood, **114**: 722.
- 16. **Kohrt, H,** Patel, S, Ho, M, Owen, T, Majeti, R, Gotlib, J, Coutre, S, Medeiros, B, and A Alizadeh (2009). "Is time of the essence in adult Acute Myeloid Leukemia? Time to blast clearance and time to induction therapy fail to predict overall survival." Blood, **114**: 1617.
- 17. Logan, A, Turnbull, B, Lavori, P, Miklos, D, Lowsky, R, and **H Kohrt** (2010). "The value of subset donor chimerism for predicting event-free survival differs for myeloid and lymphoid malignancies after non-myeloablative allogeneic hematopoietic cell transplantation using TLI and ATG." Biology of Blood and Marrow Transplantation, **16**(2):307.
- 18. Li, L, Kohrt, H, Heish, S, Alizadeh, A, Laport, G, Shizuru, J, Negrin, R, Strober, S, Lowsky, R, and M Sarwal (2010). "Noninvasive prediction of graft-versus-host disease following allogeneic hematopoietic cell transplantation by gene expression profiling." <u>American Journal of Transplantation</u>, 10(s4):1566.
- Pollyea, D, Kohrt, H, Rajwanshi, R, Gallegos, L, Berube, C, Coutre, S, Gotlib, J, Liedtke, M, Mitchell, B, and B Medeiros (2010). "An early-phase study of azacytidine and lenalidomide for untreated elderly acute myeloid leukemia patients." <u>Journal of Clinical Oncology</u>, 28(15):TPS280.
- 20. **Kohrt, H,** Houot, R, Goldstein, M, Weiskopf, K, Chen, L, Tedder, T and R Levy (2010). "CD137 stimulation enhances anti-tumor activity of rituximab." Journal of Clinical Oncology, **28**(15):8068.

- 21. **Kohrt, H,** Houot, R, Goldstein, M, Weiskopf, K, Chen, L, Tedder, T and R Levy (2010). "CD137 stimulation enhances anti-tumor activity of rituximab." <u>Haematologica</u>, **95**(s2):305.
- 22. **Kohrt, H,** Lund, P, Colevas, D, Weiskopf, K, Levy, R, and J Sunwoo (2010). "Enhancement of cetuximab therapy with anti-CD137 in treatment of squamous cell carcinoma." <u>Archives of Otolaryngology</u>, Head and Neck Surgery, (33):1.
- 23. Alizadeh, A, Gentles, A, Alencar, A, **Kohrt, H,** Houot, R, Goldstein, M, Zhao, S, Natkunam, Y, Advani, A, Gascoyne, R, Briones, J, Tibshirani, R, Myklebust, J, Plevritis, S, Lossos, I, and R Levy (2010). "Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes reflecting tumor and microenvironment." <u>Blood</u> (116):2006.
- 24. Myklebust, J, Irish, J, Brody, J, Alizadeh, A, Czerwinski, D, Houot, R, **Kohrt, H,** Kolstad, A, and R Levy (2010). "NF-κB signaling in response to CpG stratifies mantle cell lymphoma patient outcome." Blood (116):144.
- 25. Medeiros, B, **Kohrt, H,** Rajwanshi, R, Gotlib, J, Coutre, S, Liedtke, M, Berube, C, Zhang, Z, Arber, D, and J Zehnder (2010). "Temozolomide In acute myeloid leukemia: A MGMT promoter methylation status-based treatment stratification." <u>Blood</u> (116):3313.
- 26. Pollyea, D, **Kohrt, H,** Gallegos, L, Berube, C, Coutre, S, Gotlib, J, Liedtke, M, Mitchell, B, and B Medeiros (2010). "A phase I study of sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia." <u>Blood</u> (116):3288.
- 27. Alizadeh, A, Anderson, M, **Kohrt, H,** Shyam, R, Bangs,C, Cherry, A, Advani, R, Natkunam, Y, and R Levy (2010). "Clinical and pathological features of non-hodgkin lymphomas harboring concurrent t(14;18) and 8q24 anomalies." Blood (116):3134.
- 28. Goldstein, M, **Kohrt, H,** Houot, R, Varghese, B, Lin, J, Swanson, E, and R Levy (2010). "CD137 identifies a population of regulatory T cells that inhibit anti-tumor immune responses in adoptive immunotherapy." <u>Blood</u> (116):2093.
- 29. **Kohrt, H,** Houot, R, Goldstein, M, Weiskopf, K, Alizadeh, Chen, L, Tedder, T, and R Levy (2010). "Immunomodulation of NK cells through 4-1BB to improve anti-lymphoma activity of rituximab: antibody-based anti-lymphoma synergy." <u>Blood</u> (116):422.
- 30. **Kohrt, H,** Li, Li, Alizadeh, A, Goldstein, M, Strober, S, Sarwal, M, and R Lowsky (2010). "Noninvasive prediction of graft-verus-host disease following allogeneic hematopoietic cell transplantation by gene expression profiling." Blood (116):896.
- 31. Pollyea, D, **Kohrt, H,** Zhang, B, Zehnder, J, Schenkein, D, Fantin, V, Straley, K, Vasanthakumar, A, Abdel-Wahab, O, Levine, R, Godley, L, and B Medeiros (2011). "2-Hydroxyglutarate in IDH mutant AML: Predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels." <u>Blood</u> (118):2509.
- 32. Brody, J, Czerwinski, D, Carlton, V, Moorhead, M, Zheng, J, Klinger, M, Faham, M, Advani, R, **Kohrt, H,** Alizadeh, A, Negrin, R, Weng, W, Sheehan, K, and R Levy (2011). "Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results." <u>Blood</u> (118):3068.
- 33. Gill, S, Vasey, A, Baker, J, Smith, A, **Kohrt, H,** Florek, M, Ritchie, D, and R Negrin (2011). "Natural killer cell adoptive immunotherapy is hampered by a rapid development of NK cell dysfunction characterized by loss of effector mechanisms and downregulation of the transcription factors T-bet and eomesodermin; definition and possible mechanism of NK cell exhaustion." Blood (118):1000.
- 34. **Kohrt, H,** Mueller, A, Baker, J, Goldstein, M, Newell, E, Dutt, S, Czerwinski, D, Lowsky, R, and S Strober (2011). "Donor immunization with WT1 peptide augments anti-leukemic activity after MHC-matched bone marrow transplantation." Blood (118):1896.

- 35. **Kohrt, H,** Houot, R, Weiskopf, K, Goldstein, M, Lund, P, Czerwinski, D, Sunwoo, J, Tedder, T, Chen, L, and R Levy (2012). "Stimulation of natural killer cells with an anti-CD137 antibody enhances the efficacy trastuzumab, cetuximab, and rituximab in HER2-expressing breast cancer, EGFR+ head and neck cancer, and CD20+ lymphoma." <u>Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research.</u>
- 36. Marabelle, A, **Kohrt, H,** Brody, J, Torchia, J, Rajapaksa, R, Luong, R, Zhou, G, Levtisky, H, Tse, V, and R Levy (2012). "In situ Treg immunomodulation at a single tumor site with CpG and immune checkpoint antibodies cures metastatic disease." <u>Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research</u>.